---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011201"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:44:09.783081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale

## Summary
- Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.
- Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.
- Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.
- Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.
- R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions.

## SEC filing metadata
- accession: 0001558370-24-011201
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/0001558370-24-011201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/acrs-20240807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011201
- JSON: https://secwatch.observer/filing/0001558370-24-011201.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.